DeepMind spinout Isomorphic Labs raises $2.1bn
Summary
DeepMind spinout Isomorphic Labs, focused on AI-designed drugs, has secured $2.1 billion in a Series B funding round led by US venture firm Thrive Capital. This investment follows a $600 million raise in May of the previous year. Key participants in the latest round include the UK's Sovereign AI fund, Abu Dhabi's MGX, Alphabet's GV, and Singapore's Temasek. Launched in 2021 by Colin Murdoch and Demis Hassabis, Isomorphic Labs utilizes Google DeepMind's AlphaFold technology, an AI system for protein structure prediction, to develop its drug discovery platform. The company has already established partnerships with pharmaceutical giants like Eli Lilly and Novartis and has initiated pre-clinical trials for its proposed drugs.
Key takeaway
For investors evaluating AI-driven biotech firms, Isomorphic Labs' successful $2.1 billion Series B, backed by sovereign funds and major VCs, signals strong market confidence in its AlphaFold-powered drug discovery platform. Your due diligence should focus on its pre-clinical trial progress and the strategic value of its pharmaceutical partnerships with companies like Eli Lilly and Novartis, as these indicate tangible advancement and market validation.
Key insights
AI-driven drug discovery benefits from specialized teams and distinct corporate structures.
Principles
- Specialized talent drives innovation.
- Clear mission fosters distinct culture.
In practice
- Spin out ventures for specialized talent.
- Leverage AI for protein structure prediction.
Topics
- Isomorphic Labs
- AI Drug Discovery
- Venture Capital Funding
- AlphaFold Technology
- DeepMind Spinout
Best for: Investor, Entrepreneur, Research Scientist
Related on AIssential
Editorial summary, takeaway, and curation by AIssential. Original article published by Sifted.